J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback

Phase 3positiveNeutral

AI Analysis

Summary

J&J beat Q3 expectations but underwhelmed; BMS reported Phase 3 win for RayzeBio acquisition and mixed pulmonary fibrosis data; Revolution Medicines' newly approved pancreatic cancer drug shows better efficacy in patients with specific mutations; Caribou Biosciences faces potential exit.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

BMS Phase 3 win validating RayzeBio acquisition; mixed data in pulmonary fibrosis trial

Importance:7/10

Sentiment:

0.20

earningsPhase 3 dataacquisitionpancreatic cancerpulmonary fibrosisdrug approval

Related Companies

$JNJ $CELG-RI $RVMD $CRBU

Read the original article

Published by BioSpace on October 14, 2026 9:44 AM

Read Original